Loading
TER-2013 is an experimental oral small-molecule inhibitor from Terremoto Biosciences, in phase 1 trials for HR-positive HER2-negative breast cancer with PIK3CA, AKT1 or PTEN alterations, endometrial cancer and ovarian cancer and other cancers.
TER-2013 is an oral small-molecule inhibitor (AKT1-selective) from Terremoto Biosciences. An oral small molecule designed to selectively inhibit AKT1 while sparing AKT2 and AKT3, aiming to avoid the AKT2-linked high blood sugar, and the rash and diarrhoea, seen with earlier pan-AKT inhibitors. Its furthest stage is phase 1, for HR-positive HER2-negative breast cancer with PIK3CA, AKT1 or PTEN alterations, endometrial cancer, ovarian cancer and cervical cancer. ClinicalTrials.gov registers it in one study linked below. Registry: NCT07109726 phase 1/2, recruiting (start 2025-09-23). Company pipeline says it is 'currently being evaluated in a Phase 1 clinical trial'. FDA Fast Track per company release dated 3 June 2026. Whether it works in people has not been established unless a trial below reports it.
An oral small molecule designed to selectively inhibit AKT1 while sparing AKT2 and AKT3, aiming to avoid the AKT2-linked high blood sugar, and the rash and diarrhoea, seen with earlier pan-AKT inhibitors. Connects to AKT.
1.TER-2013 slips into a pocket on AKT.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TER-2013" OR ABSTRACT:"TER-2013") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TER-2013, not a curated reading list.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endometrial cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Cervical cancer, Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/